Issue 4/2012

  • Can bioeconomy save the planet?

    In this issue:

    • Swiss Biotech Report reveals more investment in sector
    • Danes kick-off psychiatric genomics research hub
    • Wellcome Trust to aid UK biotech with £200m in funding
    • Analytica 2012 in Munich: Update on bioanalytics
    • Janus to commercialise inclusion body drug delivery system
    • Mabion announces IPO on Warsaw Stock Exchange
    • Intratumour heterogeneity challenges biomarker approach

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/4/pos/1.html?sort=desc&cHash=8305edff5982cb307c5ea48106acb36a

Kurszettel

Alle Kurse

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.16 EUR46.2%
  • FORMYCON10.90 EUR38.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.59 EUR-10.7%
  • ADDEX2.99 CHF-9.4%

TOP

  • SANTHERA92.95 CHF2525.7%
  • CO.DON2.65 EUR154.8%
  • BB BIOTECH183.40 EUR63.9%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-48.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 25.11.2014